Adult Malignant Glioma Therapeutics Market Overview
Adult Malignant Glioma Therapeutics Market size is estimated to reach $3.1 billion by 2027, growing at a CAGR of 9.5% during the forecast period 2022-2027. Adult Malignant Glioma involves malignant gliomas, the most typical kind of primary brain tumor in mature grown-ups, which are connected with disproportionate cancer-related morbidity and mortality. Currently, there have been significant advancements in the comprehension of the molecular pathogenesis of malignant gliomas and breakthroughs in treating them. The standardized examination was directed to establish guidelines for radiotherapy in mature grown-up patients with newly diagnosed malignant glioma. Post-operative external beam radiotherapy is suggested as standard therapy for patients with malignant glioma. Molecularly targeted therapy is revolutionizing the care of patients with malignant gliomas, involving glioblastoma, the most typical malignant principal brain tumor of mature grown-ups. Vascular endothelial growth factor (VEGF) is an appealing target of antiangiogenic therapy in glioblastomas. Bevacizumab (Bev), a humanized anti-VEGF antibody, is connected with the enhancement of progression-free survival and performance status in patients with glioblastoma. Carmustine (BCNU), a low-molecular-weight alkylating agent, has well recognized action against malignant gliomas. Temozolomide, a novel medication, has demonstrated promise in treating malignant gliomas and additional hard-to-treat tumors. Temozolomide, a p.o. imidazotetrazine second-generation alkylating agent, is the chief compound in a novel class of chemotherapeutic agents that enter the cerebrospinal fluid and do not need hepatic metabolism for activation. Monoclonal antibody (mAb) therapy involving monoclonal antibodies is an expeditiously evolving treatment immunotherapy modality for malignant gliomas.
The increasing predominance of cancer-connected ailments globally and burgeoning cases of brain tumors with the application of stereotactic radiotherapy (SRT) for small brain tumors are set to drive the Adult Malignant Glioma Therapeutics Market. The proliferating acceptance of an unhealthy lifestyle, genetic modification/alteration, raised age, enormous exposure to radiation and family history with brain cancer are set to propel the growth of the Adult Malignant Glioma Therapeutics Industry during the forecast period 2022-2027. This represents the Adult Malignant Glioma Therapeutics Industry Outlook.
Adult Malignant Glioma Therapeutics Market Report Coverage
The report: “Adult Malignant Glioma Therapeutics Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Adult Malignant Glioma Therapeutics Market.
By Type Of Disease: Glioblastoma Multiforme,
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic
By Therapy: Chemotherapy, Targeted Drug Therapy, Radiation Therapy.
By End-use Industry: Specialty Clinics, Hospitals, Cancer And Radiation Therapy Centers, Others.
By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America) and Rest Of The World (Middle East, Africa).
- Geographically, North America (Adult Malignant Glioma Therapeutics market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the extensive technological progress in Adult Malignant Glioma Therapeutics involving radiotherapy, targeted therapy and monoclonal antibodies in the North American region.
- Adult Malignant Glioma Therapeutics Market growth is being driven by the consistent increasing predominance of adult malignant glioma across the world requiring the application of radiotherapy, targeted therapy and monoclonal antibodies. However, the soaring treatment costs, loss of market exclusivity, post-patent expiration and price decrease in branded medications attributed to competition from generic brands are some of the major factors hampering the growth of the Adult Malignant Glioma Therapeutics Market.
- Adult Malignant Glioma Therapeutics Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Adult Malignant Glioma Therapeutics Market report.
Adult Malignant Glioma Therapeutics Market: Market Share (%) by Region, 2021
For more details on this report - Request for Sample
Adult Malignant Glioma Therapeutics Market Segment Analysis - By Type of Disease
The Adult Malignant Glioma Therapeutics Market based on type of disease can be further segmented into Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Others. The Glioblastoma Multiforme Segment held the largest Adult Malignant Glioma Therapeutics market share in 2021. This growth is owing to the increasing count of patients diagnosed with Glioblastoma Multiforme driving demand for efficient therapeutics to enhance the survival rate on the whole. The backbone of treatment for GBMs is surgery, succeeded by radiation therapy and chemotherapy. The heightened focus of manufacturers on R&D activities and the accelerated boost of the pipeline of innovative novel medications are further propelling the growth of the Glioblastoma Multiforme segment.
Furthermore, the Anaplastic Astrocytoma segment is estimated to grow with the fastest CAGR of 10.1% during the forecast period 2022-2027 owing to the increasing count of surgeries being performed to treat anaplastic astrocytoma with chemotherapy and radiation therapy being applied if the tumor was not eliminated with surgery or only portion of it was only eliminated.
Adult Malignant Glioma Therapeutics Market Segment Analysis - By Therapy
The Adult Malignant Glioma Therapeutics Market based on therapy can be further segmented into Chemotherapy, Targeted Drug Therapy, Radiation Therapy. The Targeted Drug Therapy Segment held the largest Adult Malignant Glioma Therapeutics market share in 2021. This growth is owing to the extensive focus on targeted molecular therapy attributed to the poor prognosis obtained from approaches like surgery, radiotherapy and chemotherapy. Current advancements in the comprehension of the deregulated molecular pathways of gliomas have created targeted therapy that has the capability to boost therapeutic efficiency in tumors while reducing toxicity. A novel class of medications, the tyrosine kinase inhibitors, which intervene with the operation of key molecules in cancer-promoting pathways, have had a dramatic impact on hematological malignancy and are being trialed in solid tumors, inclusive of glioma. The possibility of therapeutic agents targeting the signaling pathways offering more efficient treatments and enhancing survival is further propelling the growth of this segment.
Furthermore, the Radiation Therapy segment is estimated to grow with the fastest CAGR of 10.9% during the forecast period 2022-2027 owing to the surging application of post-operative external beam radiotherapy which is suggested as standard therapy for patients with malignant glioma.
Adult Malignant Glioma Therapeutics Market Segment Analysis - By Geography
The Adult Malignant Glioma Therapeutics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Adult Malignant Glioma Therapeutics Market) held the largest Adult Malignant Glioma Therapeutics market share with 36% of the overall market in 2021. The growth of this region is owing to the increasing predominance of malignant glioma in the North American region. The standard treatment for glioblastoma includes surgical resection succeeded by radiation therapy and simultaneous chemotherapy The powerful economy, enormous spending on healthcare and soaring diagnosis rate attributed to surging awareness regarding healthcare is further propelling the growth of the Adult Malignant Glioma Therapeutics Industry, thereby contributing to the Adult Malignant Glioma Therapeutics Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the soaring patient population demanding economical care in the Asia-Pacific region. The enhancements in healthcare infrastructure assisting in the early diagnosis of malignant gliomas and the integrated prospects in technology and opportunity in the developing countries like China, Japan, India and South Korea are further fuelling the progress of the Adult Malignant Glioma Therapeutics Market in the Asia-Pacific region.
Adult Malignant Glioma Therapeutics Market Drivers
Surging Applications of Bevacizumab are Projected to Drive the Growth of Adult Malignant Glioma Therapeutics Industry:
Gliomas constitute nearly 30% of all brain and central nervous system tumors and 80% of all malignant brain tumors. Bevacizumab is a genetically engineered antibody that obstructs the development of novel blood vessels in tumors. Restricting the formation of these blood vessels may delay or halt ailment progression by declining the supply of life-nourishing nutrients and oxygen the blood delivers to the tumor. Bevacizumab is certified for treating colorectal cancer and has demonstrated action against brain tumor cells in laboratory and animal tests. Efficiency and security of bevacizumab in the treatment of adult gliomas has been investigated. Glioblastoma multiforme (GBM) has a very poor prognosis and novel treatment strategies are critically required. GBM seems to be an optimal target for anti-angiogenic therapy as the tumour demonstrates a soaring degree of endothelial cell proliferation and pro-angiogenic growth factor expression. Anti-angiogenic therapy has satisfied the proof of concept in glioma animal models. In glioma patients, the efficiency of anti-angiogenic mono-therapies at first has been unsatisfactory. However current clinical trials integrating bevacizumab, an anti-VEGF antibody, with chemotherapy recorded very promising response rates. The surging applications of Bevacizumab are therefore fuelling the growth of the Adult Malignant Glioma Therapeutics Industry, thereby contributing to the Adult Malignant Glioma Therapeutics Industry Outlook, during the forecast period 2022-2027.
Soaring Applications of Carmustine, Temozolomide and Monoclonal Antibodies are Expected to Boost the Growth of the Adult Malignant Glioma Therapeutics Market:
Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) happen more frequently than other types of primary central nervous system tumors, having a combined incidence of 5-8/100,000 population. Glioblastoma (GBM) is the most combative kind of principal malignant brain tumor. Carmustine is utilized by intravenous injection or local implantation in the resection cavity for gliomas, inclusive of GBMs. The outcomes of investigations conducted indicate that twenty-two eligible randomized controlled trials (RCTs) and companion examinations including 5,821 glioma patients were involved. On the whole, glioma patients accepting carmustine as an adjuvant therapy had superior progression-free survival [PFS; hazard ratio (HR) = 0.85, 95% CI = 0.77–0.94, P = 0.002] and on the whole survival (OS; HR = 0.85, 95% CI = 0.79–0.92, P < 0.0001) than those without carmustine treatment. The outcomes of certain investigations recommend that the integration of clinically relevant temozolomide (TMZ) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- -secreting human mesenchymal stem cells (MSC-TRAIL) is a promising therapeutic strategy for enhancing the treatment of malignant gliomas. Infusion of radiolabeled monoclonal antibodies (MAbs) directly into a tumor or into the site of ailment consequent to surgery concentrates a soaring amount of antibody and radioisotope in the neoplastic tissue. The powerful irradiation conveyed by this technique can lead to the control of high-grade malignant gliomas. The soaring applications of Carmustine, Temozolomide and Monoclonal Antibodies are therefore driving the growth of the Adult Malignant Glioma Therapeutics Market during the forecast period 2022-2027.
Adult Malignant Glioma Therapeutics Market Challenge
Challenges of Adult Malignant Glioma Therapeutics are Hampering the Growth of the Adult Malignant Glioma Therapeutics Market:
The Adult Malignant Glioma Therapeutics market is characterized by an inadequate medical requirement of enhancing survival rates. The market is perceiving an accelerated boost in novel pipeline medication candidates from the principal as well as rising market players, backed by government policies to accelerate the process of orphan drug approval. Orphan drugs (ODs) are medicines utilized to treat rare medical conditions. They can be costly. In 1983, the U.S. government passed the Orphan Drug Act (ODA) to drive novel development in OD medicines to treat rare ailments. To date, the ODA has backed the approval of greater than 600 medicines for rare ailments. Glioblastoma (GBM) is the most combative diffuse glioma of astrocytic lineage and is treated a grade IV glioma based on the World Health Organization (WHO) classification. GBM is the most typical malignant principal brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM stays as an incurable tumor with a median survival of only 15 months. Treatment is complicated, at first including maximally secure surgical resection succeeded by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy. These issues are thus hampering the growth of the Adult Malignant Glioma Therapeutics Market.
Adult Malignant Glioma Therapeutics Industry Outlook
Mergers and acquisitions, investments, expansions of capacity, plant turnarounds, novel product developments and launches, joint ventures and R&D activities are key strategies adopted by players in the Adult Malignant Glioma Therapeutics Market. The top 10 companies in the Adult Malignant Glioma Therapeutics market are:
- Merck & Co. Inc.
- F. Hoffmann-La Roche Ltd.
- Arbour Pharmaceuticals LLC
- Bristol-Myers Squibb Company
- Bio-Rad Laboratories
- AbbVie Inc.
- Amgen Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- In June 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. presently declared a definitive merger agreement under which Bristol Myers Squibb will gain Turning Point Therapeutics for $76.00 per share. The transaction was collectively certified by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is predicted to close in the course of the third quarter of 2022. Turning Point Therapeutics is a clinical-stage precision oncology firm with a pipeline of investigational medications planned to target the most typical mutations connected with oncogenesis.
- In April 2021, Roche declared a range of five novel planned applications for two key cardiac biomarkers utilizing the Elecsys® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers have been verified to be successful in backing cardiovascular disease handling and can assist clinicians diagnose heart attacks (cTnT-hs) and superior handling of heart failure (NT-proBNP). Roche's launch of five novel planned applications for these existing, globally accepted diagnostic solutions means greater people could gain advantage from enhanced cardiovascular diagnostics.
- In January 2021, Roche presently declared the CE-IVD introduction of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to assist in deciding the best treatment strategy for every patient. The image analysis algorithms utilize artificial intelligence to back pathologists in making quicker, more precise patient diagnoses in breast cancer. A mutation in the HER2 gene, which happens in as many as 20 percent of the 2.1million cases of breast cancer diagnosed worldwide every year, is accountable for aggressive growth in certain patients. This concludes the Adult Malignant Glioma Therapeutics Industry Outlook.
Adult Vitamin Gummies Market - Industry Analysis, Market
Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: FBR 58539
For more Lifesciences and Healthcare related reports, please click here